Mabvax Therapeutics Holdings Inc

Find more results for Philip R Kaplan�

Officers and directors

J. David Hansen
Chairman of the Board, President, Chief Executive Officer
Gregory P. Hanson
Chief Financial Officer
Wendy K. Wee
Principal Accounting Officer, Vice President - Finance, Controller
Philip O. Livingston M.D.
Chief Science Officer, Director
William P. Kaplan Esq.
Vice President, General Counsel, Corporate Secretary, Vice President - Legal Affairs
Wolfgang W. Scholz Ph.D.
Vice President - Antibody Discovery
Steven R. Schow Ph.D.
Vice President - Research
Kenneth M. Cohen
Robert E. Hoffman
Paul V. Maier


11588 Sorrento Valley Rd Ste 20
SAN DIEGO, CA 92121-1336
United States - Map
+1-858-2599405 (Phone)

Website links

MabVax Therapeutics Holdings, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of human monoclonal antibody products and vaccines for the treatment of a variety of cancers. The Company has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. The Company�s lead antibody candidate, 5B1, is being developed for the treatment of pancreatic cancer. The Company has completed additional Phase I vaccine clinical trials in melanoma, ovarian cancer, and small cell lung cancer. The Company is also developing the 5B1 antibody conjugated to a radiolabel as positron Emission tomography imaging agent to assist in the diagnosis of pancreatic cancer.

Related companies

* Delayed by up to 20 minutes -  Disclaimer